









Markets
/
Stocks
/
nasdaq-tovx
/

Theriva Biologics Inc

TOVX

0.297USD

-0.028-8.52%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

2.69MMarket Cap

LossP/E TTM



Theriva Biologics Inc

0.297

-0.028-8.52%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Theriva Biologics Inc

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Theriva Biologics Inc's Score

Industry at a Glance

Industry Ranking

199 / 407

Overall Ranking

344 / 4616

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Buy

Current Rating

7.000

Target Price

+2053.85%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Theriva Biologics Inc Highlights

StrengthsRisks

Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. It is advancing a new oncolytic adenovirus platform. Its candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01 is an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment. SYN-004 (ribaxamase) is designed to degrade certain commonly used intravenous beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage. SYN-020 is a recombinant oral formulation of the enzyme intestinal alkaline phosphatase produced under current good manufacturing practice conditions and intended to treat both local GI and systemic diseases. Its research programs include VCN-11 Albumin Shield Technology and SYN-006, SYN-007, other oncolytic virus.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Overvalued

The company’s latest PE is -0.07, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 320.68K shares, decreasing 69.07% quarter-over-quarter.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of -0.45.

Financial Health

Currency: USD Updated: 2025-11-04

The company's current financial score is 7.10, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.10

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.74

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Theriva Biologics Inc's Company Valuation

Currency: USD Updated: 2025-11-04

The company’s current valuation score is 7.14, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -0.07, which is -53.48% below the recent high of -0.03 and -30570.64% above the recent low of -21.62.

Score

Industry at a Glance

Previous score

7.14

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 199/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-04

The company’s current earnings forecast score is 7.00, which is lower than the Biotechnology & Medical Research industry's average of 8.00. The average price target for Theriva Biologics Inc is 7.00, with a high of 7.00 and a low of 7.00.

Score

Industry at a Glance

Previous score

7.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts

Buy

Current Rating

7.000

Target Price

+2053.85%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Theriva Biologics Inc

TOVX

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-04

The company’s current price momentum score is 3.98, which is lower than the Biotechnology & Medical Research industry's average of 6.41. Sideways: Currently, the stock price is trading between the resistance level at 0.68 and the support level at 0.10, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

3.90

Change

0.08

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.017

Sell

RSI(14)

42.767

Neutral

STOCH(KDJ)(9,3,3)

4.218

Oversold

ATR(14)

0.108

Low Volatility

CCI(14)

-71.681

Neutral

Williams %R

97.478

Oversold

TRIX(12,20)

-1.284

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.314

Sell

MA10

0.321

Sell

MA20

0.391

Sell

MA50

0.403

Sell

MA100

0.426

Sell

MA200

0.773

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-04

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Ikarian Capital LLC

120.03K

Citadel Advisors LLC

36.02K

Boothbay Fund Management, LLC

35.60K

Virtu Americas LLC

34.49K

Geode Capital Management, L.L.C.

18.60K

-0.44%

Two Sigma Investments, LP

17.82K

XTX Markets LLC

17.19K

Intracoastal Capital

15.70K

-88.79%

The Vanguard Group, Inc.

Star Investors

13.95K

Shallcross (Steven A)

13.10K

+31.00%

Risk Assessment

Currency: USD Updated: 2025-11-04

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.47. The company's beta value is 0.34. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.